SAT0361 CARDIOVASCULAR RISK FACTORS AND COMORBIDITIES IN PATIENTS WITH PSA, RA AND THE GENERAL POPULATION
Authors: Anton Landgren, Lennart T.H. Jacobsson, Mats Dehlin, Ulrika Bergsten, Eva Klingberg
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Patients with psoriatic arthritis (PsA) have previously been reported to have increased cardiovascular morbidity and mortality compared to psoriasis, rheumatoid arthritis (RA) and the general population (GP). Obesity has been linked to an increased risk of developing PsA and to be higher in patients with PsA compared to those with psoriasis, RA and GP. Furthermore, obese patients with PsA are more likely to have high disease activity and a reduced response to treatment. Few studies have reported on life style data in combination with traditional cardiovascular risk factors in patients with PsA compared to GP and RA in the same setting. <h3>Objectives:</h3> We aimed to assess cardiovascular risk factors in patients with PsA compared to age- and sex matched RA and GP subjects. <h3>Methods:</h3> We performed a cross-sectional study in the Western Sweden Health Care Region (WSHCR). All Individuals who were ≥18 and had at least one ICD-10 diagnosis for PsA (ICD-10 codes M073) or RA (ICD 10 codes M059 and M060), at a visit at any of three rheumatology clinics in the WSHCR during a two-year period (Jan 2015 through Feb 2017) were identified. From these we randomly selected PsA patients (n=1200) and RA patients (n=1246), with equal sex distribution and they were sent a postal questionnaire. Data for non-responders were limited to age and sex. The questionnaire included questions on demographics, comorbidities, smoking, alcohol consumption, physical activity, medications and disease specific entities. The National public health survey from 2015, "Health on equal terms", which was sent to randomly selected citizens in Sweden aged 16-84, was used as a sex- and aged matched reference population with five controls matched per RA and PsA case. Obesity was defined according to WHO standards as BMI ≥30. Daily smoking, alcohol consumption (≥5 standard drinks of alcohol per week) and physical activity (≥3 hours per week) were also analyzed. <h3>Results:</h3> Response rates were n=687 (57.3%) for PsA and n=742 (59.6%) for RA. After age- and sex matching there were 432 individuals with PsA, 431 with RA and 4314 matched subjects from the general population left for analyses. Mean age was 61.1 (SD 12.0) years and 42% males in all three groups. Patients with PsA were more frequently obese, compared to both GP (p&lt;0.001) and RA (p=0.012). Smoking was more prevalent in RA and PsA than in GP. In addition, hypertension was more common in PsA compared to RA (p=0.044) and GP (p&lt;0.001). Diabetes was also more prevalent in PsA than in GP (p=0.007), as was hyperlipidemia (p=0.039). Patients with PsA drank more often ≥5 standard drinks of alcohol per week than patients with RA did (p=0.046). <h3>Conclusion:</h3> In PsA, obesity and comorbidities related to CVD were increased above what was seen for both RA compared to the GP. This highlights the need to address these partly modifiable factors in particular for patients with PsA <h3>Disclosure of Interests:</h3> Anton Landgren: None declared, Lennart T.H. Jacobsson Consultant for: LJ has received lecture and consulting fees from Pfizer, Abbvie, Novartis, Eli-Lily and Janssen, Mats Dehlin: None declared, Ulrika Bergsten: None declared, Eva Klingberg Grant/research support from: Unrestricted grant from Roche, Consultant for: Novartis, Speakers bureau: Speakers fee from Lilly